Continuous Manufacturing Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Continuous Manufacturing Market, By Therapeutics Type

7.1.  Continuous Manufacturing Market, By Therapeutics Type, 2020-2030

7.1.1.    Large Molecules

7.1.1.1.        Market Revenue and Forecast (2016-2030)

7.1.2.    Small Molecules

7.1.2.1.        Market Revenue and Forecast (2016-2030)

Chapter 8.  Global Continuous Manufacturing Market, By Application Type

8.1.  Continuous Manufacturing Market, By Application Type, 2020-2030

8.1.1.    Finished Product Manufacturing

8.1.1.1.        Market Revenue and Forecast (2016-2030)

8.1.2.    API Manufacturing

8.1.2.1.        Market Revenue and Forecast (2016-2030)

Chapter 9.  Global Continuous Manufacturing Market, By Formulation Type

9.1.  Continuous Manufacturing Market, By Formulation Type, 2020-2030

9.1.1.    Solid Formulation

9.1.1.1.        Market Revenue and Forecast (2016-2030)

9.1.2.    Liquid & Semi-solid Formulation

9.1.2.1.        Market Revenue and Forecast (2016-2030)

Chapter 10.      Global Continuous Manufacturing Market, By Mode Type

10.1.        Continuous Manufacturing Market, By Mode Type, 2020-2030

10.1.1.  In-House

10.1.1.1.      Market Revenue and Forecast (2016-2030)

10.1.2.  Contract

10.1.2.1.      Market Revenue and Forecast (2016-2030)

Chapter 11.      Global Continuous Manufacturing Market, By Sales Type

11.1.        Continuous Manufacturing Market, By Sales Type, 2020-2030

11.1.1.  Preclinical

11.1.1.1.      Market Revenue and Forecast (2016-2030)

11.1.2.  Clinical

11.1.2.1.      Market Revenue and Forecast (2016-2030)

11.1.3.  Commercial

11.1.3.1.      Market Revenue and Forecast (2016-2030)

Chapter 12.      Global Continuous Manufacturing Market, By Product Type

12.1.        Continuous Manufacturing Market, By Application Type, 2020-2030

12.1.1.  Integrated Systems

12.1.1.1.      Market Revenue and Forecast (2016-2030)

12.1.2.  Semi-continuous Systems

12.1.2.1.      Market Revenue and Forecast (2016-2030)

Chapter 13.      Global Continuous Manufacturing  Market, Regional Estimates and Trend Forecast

13.1.        North America

13.1.1.  Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.1.2.  Market Revenue and Forecast, By Application (2016-2030)

13.1.3.  Market Revenue and Forecast, By Formulation (2016-2030)

13.1.4.  Market Revenue and Forecast, By Mode (2016-2030)

13.1.5.  Market Revenue and Forecast, By Sales Type (2016-2030)

13.1.6.  Market Revenue and Forecast, By Product Type (2016-2030)

13.1.7.  U.S.

13.1.7.1.      Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.1.7.2.      Market Revenue and Forecast, By Application (2016-2030)

13.1.7.3.      Market Revenue and Forecast, By Formulation (2016-2030)

13.1.7.4.      Market Revenue and Forecast, By Mode (2016-2030)

13.1.8.  Market Revenue and Forecast, By Sales Type (2016-2030)

13.1.8.1.      Market Revenue and Forecast, By Product Type (2016-2030)

13.1.9.  Rest of North America

13.1.9.1.      Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.1.9.2.      Market Revenue and Forecast, By Application (2016-2030)

13.1.9.3.      Market Revenue and Forecast, By Formulation (2016-2030)

13.1.9.4.      Market Revenue and Forecast, By Mode (2016-2030)

13.1.10.               Market Revenue and Forecast, By Sales Type (2016-2030)

13.1.11.               Market Revenue and Forecast, By Product Type (2016-2030)

13.1.11.1.    

13.2.        Europe

13.2.1.  Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.2.2.  Market Revenue and Forecast, By Application (2016-2030)

13.2.3.  Market Revenue and Forecast, By Formulation (2016-2030)

13.2.4.  Market Revenue and Forecast, By Mode (2016-2030)

13.2.5.  Market Revenue and Forecast, By Sales Type (2016-2030)

13.2.6.  Market Revenue and Forecast, By Product Type (2016-2030)

13.2.7.   

13.2.8.  UK

13.2.8.1.      Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.2.8.2.      Market Revenue and Forecast, By Application (2016-2030)

13.2.8.3.      Market Revenue and Forecast, By Formulation (2016-2030)

13.2.9.  Market Revenue and Forecast, By Mode (2016-2030)

13.2.10.               Market Revenue and Forecast, By Sales Type (2016-2030)

13.2.10.1.   Market Revenue and Forecast, By Product Type (2016-2030)

13.2.11.               Germany

13.2.11.1.   Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.2.11.2.   Market Revenue and Forecast, By Application (2016-2030)

13.2.11.3.   Market Revenue and Forecast, By Formulation (2016-2030)

13.2.12.               Market Revenue and Forecast, By Mode (2016-2030)

13.2.13.               Market Revenue and Forecast, By Sales Type (2016-2030)

13.2.14.               Market Revenue and Forecast, By Product Type (2016-2030)

13.2.14.1.    

13.2.15.               France

13.2.15.1.   Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.2.15.2.   Market Revenue and Forecast, By Application (2016-2030)

13.2.15.3.   Market Revenue and Forecast, By Formulation (2016-2030)

13.2.15.4.   Market Revenue and Forecast, By Mode (2016-2030)

13.2.16.               Market Revenue and Forecast, By Sales Type (2016-2030)

13.2.16.1.   Market Revenue and Forecast, By Product Type (2016-2030)

13.2.17.               Rest of Europe

13.2.17.1.   Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.2.17.2.   Market Revenue and Forecast, By Application (2016-2030)

13.2.17.3.   Market Revenue and Forecast, By Formulation (2016-2030)

13.2.17.4.   Market Revenue and Forecast, By Mode (2016-2030)

13.2.18.               Market Revenue and Forecast, By Sales Type (2016-2030)

13.2.18.1.   Market Revenue and Forecast, By Product Type (2016-2030)

13.3.        APAC

13.3.1.  Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.3.2.  Market Revenue and Forecast, By Application (2016-2030)

13.3.3.  Market Revenue and Forecast, By Formulation (2016-2030)

13.3.4.  Market Revenue and Forecast, By Mode (2016-2030)

13.3.5.  Market Revenue and Forecast, By Sales Type (2016-2030)

13.3.6.  Market Revenue and Forecast, By Product Type (2016-2030)

13.3.7.  India

13.3.7.1.      Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.3.7.2.      Market Revenue and Forecast, By Application (2016-2030)

13.3.7.3.      Market Revenue and Forecast, By Formulation (2016-2030)

13.3.7.4.      Market Revenue and Forecast, By Mode (2016-2030)

13.3.8.  Market Revenue and Forecast, By Sales Type (2016-2030)

13.3.9.  Market Revenue and Forecast, By Product Type (2016-2030)

13.3.10.               China

13.3.10.1.   Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.3.10.2.   Market Revenue and Forecast, By Application (2016-2030)

13.3.10.3.   Market Revenue and Forecast, By Formulation (2016-2030)

13.3.10.4.   Market Revenue and Forecast, By Mode (2016-2030)

13.3.11.               Market Revenue and Forecast, By Sales Type (2016-2030)

13.3.11.1.   Market Revenue and Forecast, By Product Type (2016-2030)

13.3.12.               Japan

13.3.12.1.   Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.3.12.2.   Market Revenue and Forecast, By Application (2016-2030)

13.3.12.3.   Market Revenue and Forecast, By Formulation (2016-2030)

13.3.12.4.   Market Revenue and Forecast, By Mode (2016-2030)

13.3.12.5.   Market Revenue and Forecast, By Sales Type (2016-2030)

13.3.12.6.   Market Revenue and Forecast, By Product Type (2016-2030)

13.3.13.               Rest of APAC

13.3.13.1.   Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.3.13.2.   Market Revenue and Forecast, By Application (2016-2030)

13.3.13.3.   Market Revenue and Forecast, By Formulation (2016-2030)

13.3.13.4.   Market Revenue and Forecast, By Mode (2016-2030)

13.3.13.5.   Market Revenue and Forecast, By Sales Type (2016-2030)

13.3.13.6.   Market Revenue and Forecast, By Product Type (2016-2030)

13.4.        MEA

13.4.1.  Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.4.2.  Market Revenue and Forecast, By Application (2016-2030)

13.4.3.  Market Revenue and Forecast, By Formulation (2016-2030)

13.4.4.  Market Revenue and Forecast, By Mode (2016-2030)

13.4.5.  Market Revenue and Forecast, By Sales Type (2016-2030)

13.4.6.  Market Revenue and Forecast, By Product Type (2016-2030)

13.4.7.  GCC

13.4.7.1.      Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.4.7.2.      Market Revenue and Forecast, By Application (2016-2030)

13.4.7.3.      Market Revenue and Forecast, By Formulation (2016-2030)

13.4.7.4.      Market Revenue and Forecast, By Mode (2016-2030)

13.4.8.  Market Revenue and Forecast, By Sales Type (2016-2030)

13.4.9.  Market Revenue and Forecast, By Product Type (2016-2030)

13.4.10.               North Africa

13.4.10.1.   Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.4.10.2.   Market Revenue and Forecast, By Application (2016-2030)

13.4.10.3.   Market Revenue and Forecast, By Formulation (2016-2030)

13.4.10.4.   Market Revenue and Forecast, By Mode (2016-2030)

13.4.11.               Market Revenue and Forecast, By Sales Type (2016-2030)

13.4.12.               Market Revenue and Forecast, By Product Type (2016-2030)

13.4.13.               South Africa

13.4.13.1.   Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.4.13.2.   Market Revenue and Forecast, By Application (2016-2030)

13.4.13.3.   Market Revenue and Forecast, By Formulation (2016-2030)

13.4.13.4.   Market Revenue and Forecast, By Mode (2016-2030)

13.4.13.5.   Market Revenue and Forecast, By Sales Type (2016-2030)

13.4.13.6.   Market Revenue and Forecast, By Product Type (2016-2030)

13.4.14.               Rest of MEA

13.4.14.1.   Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.4.14.2.   Market Revenue and Forecast, By Application (2016-2030)

13.4.14.3.   Market Revenue and Forecast, By Formulation (2016-2030)

13.4.14.4.   Market Revenue and Forecast, By Mode (2016-2030)

13.4.14.5.   Market Revenue and Forecast, By Sales Type (2016-2030)

13.4.14.6.   Market Revenue and Forecast, By Product Type (2016-2030)

13.5.        Latin America

13.5.1.  Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.5.2.  Market Revenue and Forecast, By Application (2016-2030)

13.5.3.  Market Revenue and Forecast, By Formulation (2016-2030)

13.5.4.  Market Revenue and Forecast, By Mode (2016-2030)

13.5.5.  Market Revenue and Forecast, By Sales Type (2016-2030)

13.5.6.  Market Revenue and Forecast, By Product Type (2016-2030)

13.5.7.  Brazil

13.5.7.1.      Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.5.7.2.      Market Revenue and Forecast, By Application (2016-2030)

13.5.7.3.      Market Revenue and Forecast, By Formulation (2016-2030)

13.5.7.4.      Market Revenue and Forecast, By Mode (2016-2030)

13.5.8.  Market Revenue and Forecast, By Sales Type (2016-2030)

13.5.8.1.      Market Revenue and Forecast, By Product Type (2016-2030)

13.5.9.  Rest of LATAM

13.5.9.1.      Market Revenue and Forecast, By Therapeutics Type (2016-2030)

13.5.9.2.      Market Revenue and Forecast, By Application (2016-2030)

13.5.9.3.      Market Revenue and Forecast, By Formulation (2016-2030)

13.5.9.4.      Market Revenue and Forecast, By Mode (2016-2030)

13.5.9.5.      Market Revenue and Forecast, By Sales Type (2016-2030)

13.5.9.6.      Market Revenue and Forecast, By Product Type (2016-2030)

Chapter 14.  Company Profiles

14.1.              Thermo Fisher Scientific, Inc.

14.1.1.  Company Overview

14.1.2.  Product Offerings

14.1.3.  Financial Performance

14.1.4.  Recent Initiatives

14.2.              Pall Corporation

14.2.1.  Company Overview

14.2.2.  Product Offerings

14.2.3.  Financial Performance

14.2.4.  Recent Initiatives

14.3.              Applikon Biotechnology

14.3.1.  Company Overview

14.3.2.  Product Offerings

14.3.3.  Financial Performance

14.3.4.  Recent Initiatives

14.4.              Sartorius Stedim Biotech

14.4.1.  Company Overview

14.4.2.  Product Offerings

14.4.3.  Financial Performance

14.4.4.  Recent Initiatives

14.5.              GEA Group Aktiengesellschaft

14.5.1.  Company Overview

14.5.2.  Product Offerings

14.5.3.  Financial Performance

14.5.4.  Recent Initiatives

14.6.              Corning Incorporated

14.6.1.  Company Overview

14.6.2.  Product Offerings

14.6.3.  Financial Performance

14.6.4.  Recent Initiatives

14.7.              Merck KGaA

14.7.1.  Company Overview

14.7.2.  Product Offerings

14.7.3.  Financial Performance

14.7.4.  Recent Initiatives

14.8.              Glatt GmbH

14.8.1.  Company Overview

14.8.2.  Product Offerings

14.8.3.  Financial Performance

14.8.4.  Recent Initiatives

14.9.              Repligen Corporation.

14.9.1.  Company Overview

14.9.2.  Product Offerings

14.9.3.  Financial Performance

14.9.4.  Recent Initiatives

14.10.           Eppendorf AG

14.10.1.               Company Overview

14.10.2.               Product Offerings

14.10.3.               Financial Performance

14.10.4.               Recent Initiatives

14.11.           Electrolab Biotech Ltd.

14.11.1.               Company Overview

14.11.2.               Product Offerings

14.11.3.               Financial Performance

14.11.4.               Recent Initiatives

14.12.           Solesis Medical

14.12.1.               Company Overview

14.12.2.               Product Offerings

14.12.3.               Financial Performance

14.12.4.               Recent Initiatives

14.13.           Scott Equipment Company

14.13.1.               Company Overview

14.13.2.               Product Offerings

14.13.3.               Financial Performance

14.13.4.               Recent Initiatives

14.14.           L.B. Bohle

14.14.1.               Company Overview

14.14.2.               Product Offerings

14.14.3.               Financial Performance

14.14.4.               Recent Initiatives

14.15.           LONZA

14.15.1.               Company Overview

14.15.2.               Product Offerings

14.15.3.               Financial Performance

14.15.4.               Recent Initiatives

14.16.           3M

14.16.1.               Company Overview

14.16.2.               Product Offerings

14.16.3.               Financial Performance

14.16.4.               Recent Initiatives

14.17.           CellGenix GmbH

14.17.1.               Company Overview

14.17.2.               Product Offerings

14.17.3.               Financial Performance

14.17.4.               Recent Initiatives

14.18.           Boehringer Ingelheim International GmbH

14.18.1.               Company Overview

14.18.2.               Product Offerings

14.18.3.               Financial Performance

14.18.4.               Recent Initiatives

14.19.           Bio-Rad Laboratories

14.19.1.               Company Overview

14.19.2.               Product Offerings

14.19.3.               Financial Performance

14.19.4.               Recent Initiatives

14.20.           Avantor, Inc.

14.20.1.               Company Overview

14.20.2.               Product Offerings

14.20.3.               Financial Performance

14.20.4.               Recent Initiatives

14.21.           Ajinomoto Bio-Pharma

14.21.1.               Company Overview

14.21.2.               Product Offerings

14.21.3.               Financial Performance

14.21.4.               Recent Initiatives

14.22.           GlaxoSmithKline

14.22.1.               Company Overview

14.22.2.               Product Offerings

14.22.3.               Financial Performance

14.22.4.               Recent Initiatives

14.23.           Continuus Pharmaceuticals

14.23.1.               Company Overview

14.23.2.               Product Offerings

14.23.3.               Financial Performance

14.23.4.               Recent Initiatives

14.24.           Arcinova

14.24.1.               Company Overview

14.24.2.               Product Offerings

14.24.3.               Financial Performance

14.24.4.               Recent Initiatives

14.25.           Amgen

14.25.1.               Company Overview

14.25.2.               Product Offerings

14.25.3.               Financial Performance

14.25.4.               Recent Initiatives

Chapter 15.  Research Methodology

15.1.              Primary Research

15.2.              Secondary Research

15.3.              Assumptions

Chapter 16.  Appendix

16.1.              About Us

Glossary of Terms